| Company Name: |
Haoyuan Chemexpress Co., Ltd.
|
| Tel: |
021-58950125 |
| Email: |
info@chemexpress.com |
| Products Intro: |
Product Name:GDC-0339
CAS:1428569-85-0
Purity:>98% Package:3500RMB/2mg
|
GDC-0339 manufacturers
- GDC-0339
-
- $2370.00 / 25mg
-
2026-05-19
- CAS:1428569-85-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | GDC-0339 Basic information |
| Product Name: | GDC-0339 | | Synonyms: | 5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide;EOS-60554;4-Thiazolecarboxamide, 5-amino-N-[5-[(4R,5R)-4-amino-5-fluorohexahydro-1H-azepin-1-yl]-1-methyl-1H-pyrazol-4-yl]-2-(2,6-difluorophenyl)-;GDC 0339,Pim,Pim kinases,inhibit,GDC0339,GDC-0339,Inhibitor | | CAS: | 1428569-85-0 | | MF: | C20H22F3N7OS | | MW: | 465.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1428569-85-0.mol |  |
| | GDC-0339 Chemical Properties |
| density | 1.61±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 52 mg/mL (111.71 mM) | | form | Solid | | pka | 9.28±0.40(Predicted) | | color | White to yellow |
| | GDC-0339 Usage And Synthesis |
| Uses | GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2]. | | in vivo | GDC-0339 (1-300 mg/kg; p.o; daily; for 21 days) is efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models[2].
GDC-0339 has a half-life of t1/2=0.9 h[2].
| Animal Model: | Female C.B-17 SCID mice, RPMI8226 human multiple myeloma xenograft mouse model[2] | | Dosage: | 1mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg, 300 mg/kg | | Administration: | Oral administration; once daily; for 21 days | | Result: | Showed dose-dependent tumor growth inhibition. |
| | IC 50 | PIM1; PIM2; PIM3 | | References | [1] Takahashi RH, et al. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metab Dispos. 2017 Oct;45(10):1084-1092. DOI:10.1124/dmd.117.076786
[2] Wang X, et al. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem. 2019 Feb 28;62(4):2140-2153. DOI:10.1021/acs.jmedchem.8b01857 |
| | GDC-0339 Preparation Products And Raw materials |
|